Acquisition of Apalutamide 60 mg tablet, under framework agreement 2023/491

This tender concerns the acquisition of Apalutamide, a medication supplied in 60 mg tablets. The procurement is being conducted under the framework agreement identified as 2023/491. Apalutamide is a type of non-steroidal antiandrogen medication used primarily in the treatment of prostate cancer. This tender indicates a specific need for this pharmaceutical product, likely for a healthcare provider, hospital, or pharmacy. The reference to a framework agreement suggests that pre-negotiated terms, pricing, and conditions are already in place, simplifying the procurement process for this specific item. The contracting authority is seeking to purchase a quantity of Apalutamide tablets as per the established framework. The objective is to ensure the availability of this critical medication for patients undergoing treatment, leveraging an existing contractual arrangement for efficiency and potentially cost-effectiveness. The tender documentation would specify the quantities required and the delivery schedule.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 337,313.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.